La Jolla Sues Shanghai Fosun to Block Gland’s Copies of Giapreza

La Jolla Pharmaceutical Co. and George Washington University filed a lawsuit against Shanghai Fosun Pharm. Group Co. and its Gland Pharma unit, whose proposed generic version of Giapreza they allege infringes 10 patents for the injectable drug.

Gland’s proposed copy is of the 2.5 milligrams-per-milliliter vial dosage of Giapreza, according to a complaint filed Tuesday in the U.S. District Court for the District of New Jersey. The drug, approved by the U.S. Food and Drug Administration in December 2017, also is available in a 0.5 mg/mL vial.

Giapreza and Xerava, a treatment for certain abdominal infections, are La Jolla’s only ...